Most sufferers with superior prostate most cancers or urothelial most cancers aren’t present process next-generation sequencing (NGS), in line with analysis printed in JAMA Community Open.
Researchers assessed developments in NGS use amongst sufferers recognized with metastatic prostate most cancers or superior urothelial carcinoma between March 1, 2015, and December 31, 2022.
The research included 11,927 sufferers with metastatic prostate most cancers, 29.3% of whom underwent NGS. The median time from analysis of metastatic illness to NGS was 13.2 months.
The speed of NGS in these sufferers rose from 19.0% in 2015 to 36.1% in 2020 however fell to 27.1% in 2022. The cumulative incidence of NGS at 1 12 months after analysis was 1.3% in 2015 and 32.7% in 2022.
The research additionally included 6490 sufferers with superior urothelial most cancers, 32% of whom underwent NGS. The median time from analysis of superior illness to NGS was 2.7 months.
The speed of NGS in these sufferers rose from 14.1% in 2015 to 48.8% in 2021 however fell to 46.6% in 2022. The cumulative incidence of NGS testing at 1 12 months after analysis was 6.9% in 2015 and 52.5% in 2022.
In each cohorts, the usage of NGS differed by race and ethnicity, socioeconomic standing, geographic location, and insurance coverage standing.
“The findings of this cohort research recommend that whereas the speed of NGS improved over time, the vast majority of sufferers … nonetheless didn’t bear NGS testing,” the researchers wrote. “Social determinants of well being, akin to race and ethnicity, SES [socioeconomic status], and insurance coverage kind, could also be related to entry to NGS testing. Upon exterior validation, these hypothesis-generating information could assist with understanding present disparities related to NGS testing and enhance entry to standard-of-care approaches and therapies by shaping well being care insurance policies.”
Disclosures: No funding supply was reported. Some research authors disclosed conflicts of curiosity. Please see the unique reference for full disclosures.
This text initially appeared on Most cancers Remedy Advisor
